Title: SARS CoV 2 Induced Coagulopathy and Potential Role of Anticoagulation: Scoping Review of Literature

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can vary on a spectrum of asymptomatic disease, to rarer manifestations like hypercoagulability especially among elderly, patients admitted in the intensive care unit (ICU) and those with preexisting comorbidities. The exact mechanism behind this phenomenon is unexplored; however studies have shown an association with elevated cytokines and severe inflammatory response which encompasses this disease. Hypercoagulability can be limited to the lungs, or present as systemic manifestations of arterial and venous thrombosis leading to mortal outcomes. Thus, careful evaluation of risk factors should be performed by physicians and treatment with anticoagulants should be modified accordingly. All COVID-19 in-patients should receive thromboprophylactic therapy. The dosage increases with increase in severity of the disease and in high risk patients. D-dimer levels and SIC score aid in identifying high risk patients and predicting outcome. This article highlights the pathophysiology behind hypercoagulability and discusses therapeutic modalities to combat this mortal consequence of SARS-CoV-2.